Abstract:Abstract Background With new drug treatments emerging, the need for early Alzheimer’s disease (AD) detection methods that can be done in a primary care setting has become urgent. Significant advances have been made in validating blood‐based AD biomarkers, but the absence of a validated, non‐invasive clinical indicator remains a barrier for determining those who might be optimal candidates for treatment. The digital clock drawing test (dCDT) has been previously shown to be related to AD PET biomarkers. However, it is unknown whether and the extent to which dCDT would predict AD as compared to blood‐based AD biomarkers. The current study used an interpretable machine learning approach to determine whether the dCDT, independently and in combination with blood‐based AD biomarkers (e.g., amyloid‐β 42 (Aβ42); total tau (T‐tau)), was predictive of incident AD. Method This study included participants from the Framingham Heart Study Generation 2 cohort (Gen 2; n = 527) who had dCDT measures, plasma Aβ42, and T‐tau. The fast interpretable greedy‐tree sums method was used to identify clinical decision rules for AD prediction. Synthetic minority oversampling technique was employed to handle the class imbalance. The predictive ability of plasma Aβ42, T‐tau and dCDT measures was evaluated by both area under the curve (AUC) and standardized partial AUC. The permutation feature importance method was used to show the importance of each measure. Result Interpretable clinical decision rules were generated as multivariate biomarker signatures for AD prediction ( Figure 1 ). The dCDT (AUC 0.859) was better at incident AD prediction than AD blood‐based biomarkers (AUC 0.839). The combination of dCDT, Aβ42, and T‐tau best predicted incident AD (AUC 0.884) ( Figure 2 ). The combination of dCDT and blood‐based biomarkers also has higher partial AUC than individual ones ( Table 1 ). The total score and information processing scores were the most important contributing dCDT measures. Conclusion These results highlight the efficiency of detecting early AD through the integration of digital measures as a clinical indicator combined with AD specific biomarkers. The interpretable decision rules have the potential to provide automated results that can be used in practical clinical settings, although external validation is warranted.

Digital Clock and Recall is superior to the Mini-Mental State Examination for the detection of mild cognitive impairment and mild dementia

Digital Clock and Recall: a digital, process-driven evolution of the Mini-Cog

Extended Application of Digital Clock Drawing Test in the Evaluation of Alzheimer's Disease Based on Artificial Intelligence and the Neural Basis

DCTclock: Clinically-Interpretable and Automated Artificial Intelligence Analysis of Drawing Behavior for Capturing Cognition

Discriminant Validity and Time‐effectiveness of A Stepwise Dementia Case‐finding Approach in an Asian Elderly Community

Estimation of diagnostic performance of dementia screening tests: Mini-Mental State Examination, Mini-Cog, Clock Drawing test and Ascertain Dementia 8 questionnaire.

Estimating dementia risk in an African American population using the DCTclock

Digital cognitive assessments as low‐burden markers for predicting future cognitive decline and tau accumulation across the Alzheimer's spectrum

EARLY DETECTION OF DEMENTIA AND MILD COGNITIVE IMPAIRMENT WITH BRAINCHECK

Early Detection of Mild Cognitive Impairment (MCI) in an At-Home Setting

The utility of the digital clock drawing test as an accurate early screening tool for those with preclinical Alzheimer’s disease

Validation of the Quick Mild Cognitive Impairment Screen in an American Sample of Patients With Mild Cognitive Impairment and Mild Dementia

EARLY DETECTION OF MILD COGNITIVE IMPAIRMENT (MCI) IN PRIMARY CARE

Current Advances in Computerized Cognitive Assessment for Mild Cognitive Impairment and Dementia in Older Adults: A Systematic Review

Digital cognitive assessments as low-burden markers for predicting future cognitive decline and tau accumulation across the Alzheimer's spectrum

Using digital assessment technology to detect neuropsychological problems in primary care settings

Remote and unsupervised digital memory assessments can reliably detect cognitive impairment in Alzheimer's disease

A Comparative Study on the Validations of Three Cognitive Screening Tests in Identifying Subtle Cognitive Decline

Performance and validation of a digital memory test across the Alzheimer's Disease continuum

Dcdt: A Digital Clock Drawing Test System For Cognitive Impairment Screening

Mild Cognitive Impairment Subtype Performance in Comparison to Healthy Older Controls on the NIH Toolbox and Cogstate